CA2998325A1 - Phospholipid compositions and use thereof to enhance spermatozoa motility and viability - Google Patents
Phospholipid compositions and use thereof to enhance spermatozoa motility and viability Download PDFInfo
- Publication number
- CA2998325A1 CA2998325A1 CA2998325A CA2998325A CA2998325A1 CA 2998325 A1 CA2998325 A1 CA 2998325A1 CA 2998325 A CA2998325 A CA 2998325A CA 2998325 A CA2998325 A CA 2998325A CA 2998325 A1 CA2998325 A1 CA 2998325A1
- Authority
- CA
- Canada
- Prior art keywords
- sperm
- phospholipids
- mixture
- ntfl
- motility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 82
- 150000003904 phospholipids Chemical class 0.000 title claims abstract description 76
- 230000004899 motility Effects 0.000 title claims abstract description 50
- 230000035899 viability Effects 0.000 title description 7
- 230000004720 fertilization Effects 0.000 claims abstract description 18
- 238000000338 in vitro Methods 0.000 claims abstract description 10
- 210000000287 oocyte Anatomy 0.000 claims abstract description 8
- 239000007864 aqueous solution Substances 0.000 claims abstract description 7
- 230000019100 sperm motility Effects 0.000 claims description 42
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 35
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 32
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 32
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 28
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 25
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 25
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 21
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 19
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 19
- 230000001965 increasing effect Effects 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 14
- 235000020778 linoleic acid Nutrition 0.000 claims description 14
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 14
- 229920001202 Inulin Polymers 0.000 claims description 13
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 13
- 229940029339 inulin Drugs 0.000 claims description 13
- 230000002708 enhancing effect Effects 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 102000002322 Egg Proteins Human genes 0.000 claims description 4
- 108010000912 Egg Proteins Proteins 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 235000015110 jellies Nutrition 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 229960004203 carnitine Drugs 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 229940087603 grape seed extract Drugs 0.000 claims description 3
- 235000002532 grape seed extract Nutrition 0.000 claims description 3
- 235000011649 selenium Nutrition 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 239000001717 vitis vinifera seed extract Substances 0.000 claims description 3
- 235000016804 zinc Nutrition 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 210000004681 ovum Anatomy 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940044950 vaginal gel Drugs 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 239000007910 chewable tablet Substances 0.000 claims 2
- 229940068682 chewable tablet Drugs 0.000 claims 2
- 229940044959 vaginal cream Drugs 0.000 claims 2
- 239000000522 vaginal cream Substances 0.000 claims 2
- 229940044952 vaginal foam Drugs 0.000 claims 2
- 239000000259 vaginal foam Substances 0.000 claims 2
- 239000000029 vaginal gel Substances 0.000 claims 2
- 239000000286 vaginal jelly Substances 0.000 claims 2
- 238000000151 deposition Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 20
- 238000005138 cryopreservation Methods 0.000 abstract description 9
- 230000009027 insemination Effects 0.000 abstract description 6
- 230000037406 food intake Effects 0.000 abstract description 4
- 238000003860 storage Methods 0.000 abstract description 3
- 238000005470 impregnation Methods 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 description 22
- 230000000694 effects Effects 0.000 description 19
- 239000000523 sample Substances 0.000 description 15
- 239000012528 membrane Substances 0.000 description 14
- 239000000693 micelle Substances 0.000 description 13
- 230000035558 fertility Effects 0.000 description 11
- 210000000170 cell membrane Anatomy 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 230000000750 progressive effect Effects 0.000 description 9
- 210000000582 semen Anatomy 0.000 description 8
- 230000009467 reduction Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 210000003495 flagella Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 208000007466 Male Infertility Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001150 spermicidal effect Effects 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- NYLGITXFVVEBLZ-UHFFFAOYSA-N 1-methylindazol-3-amine Chemical compound C1=CC=C2N(C)N=C(N)C2=C1 NYLGITXFVVEBLZ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- -1 Salts Calcium Chloride Dihydrate Chemical class 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 231100000521 sperm damage Toxicity 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Dentistry (AREA)
- Pregnancy & Childbirth (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Sperm mobility and impregnation of an oocyte is enhanced by placing sperm in an aqueous solution of phospholipids prior to in vitro fertilization or artificial insemination. The aqueous phospholipid solution can also be used during storage or cryopreservation of the sperm. Also, the motility of sperm produced or ejaculated and the environment into which it is placed is enhanced my ingestion of the phospholipid composition by the male or female, or a vaginal placement of compositions containing the phospholipids.
Description
PHOSPHOLIPID COMPOSITIONS AND USE THEREOF
TO ENHANCE SPERMATOZOA MOTILITY AND VIABILITY
Garth Nicolson, Gonzalo Ferreira de Mattos, and Robert A. Settineri CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of US Provisional Application 62/245,868 filed October 23, 2015 and US Provisional Application 62/216,269 filed September 9, 2015, both entitled PHOSPHOLIPID COMPOSITIONS AND USE THEREOF TO
ENHANCE SPERMATOZOA MOTILITY AND VIABILITY. The present application is also a CIP of US Patent Applications Serial No. 14/815,841 filed July 31, 2015, which is a CIP of US Patent Applications Serial No.14/152,938 filed January 10, 2014, now US Patent No. 9,095,507 (the '507 patent) issued August 4, 2015, which is a CIP of US Patent Applications Serial No. 13/208,255 filed August 11, 2011, now US
Patent No. 8,877,239 (the '239 patent) issued November 04, 2014, are hereby incorporated herein in their entirety by reference, including the drawings, charts, schematics, diagrams and related written description.
BACKGROUND
Field of the Invention
TO ENHANCE SPERMATOZOA MOTILITY AND VIABILITY
Garth Nicolson, Gonzalo Ferreira de Mattos, and Robert A. Settineri CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of US Provisional Application 62/245,868 filed October 23, 2015 and US Provisional Application 62/216,269 filed September 9, 2015, both entitled PHOSPHOLIPID COMPOSITIONS AND USE THEREOF TO
ENHANCE SPERMATOZOA MOTILITY AND VIABILITY. The present application is also a CIP of US Patent Applications Serial No. 14/815,841 filed July 31, 2015, which is a CIP of US Patent Applications Serial No.14/152,938 filed January 10, 2014, now US Patent No. 9,095,507 (the '507 patent) issued August 4, 2015, which is a CIP of US Patent Applications Serial No. 13/208,255 filed August 11, 2011, now US
Patent No. 8,877,239 (the '239 patent) issued November 04, 2014, are hereby incorporated herein in their entirety by reference, including the drawings, charts, schematics, diagrams and related written description.
BACKGROUND
Field of the Invention
[0002] The present invention relates to methods for maintaining or enhancing sperm motility, counteracting the effects of aging and exposure to environmental factors that can reduce sperm motility, and providing a more friendly environment in the womb or in vitro and in turn increase the likelihood of fertilization of oocytes through vaginal or in vitro insemination. It also relates to preservation of mammalian sperm for human and animal insemination, for example in livestock breeding.
Description of the Related Art
Description of the Related Art
[0003] Sperm motility is a crucial factor for successful fertilization of oocytes (i.e., conception). The composition of the plasma membrane of the sperm is one the factors influencing sperm motility. The effects of aging, exposure to oxidative entities and changes in membrane lipid composition are important factors affecting male fertility. It has also been shown that changes in sperm membrane lipid composition are important factors resulting in a reduction in motility and the likelihood of fertilization.
Peroxidation of the membrane lipids is also an important factor affecting for sperm health in adult life and as an individual ages.
Peroxidation of the membrane lipids is also an important factor affecting for sperm health in adult life and as an individual ages.
[0004] The sperm cell has a unique structure and function. The sperm cell is viable in a body different from its origin, namely a female body, and is capable of navigating through the vagina and uterus to fertilize an egg released from the ovaries.
The plasma membrane of the sperm cell also has a lipid composition different from most other cell membranes. It contains high amounts of polyunsaturated fatty acids (PUFA), particularly diPUFA (phospholipids esterified with two PUFA). PUFA are known to contribute to membrane fluidity and flexibility. The specific membrane lipid composition of the sperm cell has been found to be important for specific sperm functions promoting the creation of microdomains with different fluidity, fusogenicity, and permeability characteristics required for the sperm to navigate to, and to penetrate and fuse with the oocyte.
The plasma membrane of the sperm cell also has a lipid composition different from most other cell membranes. It contains high amounts of polyunsaturated fatty acids (PUFA), particularly diPUFA (phospholipids esterified with two PUFA). PUFA are known to contribute to membrane fluidity and flexibility. The specific membrane lipid composition of the sperm cell has been found to be important for specific sperm functions promoting the creation of microdomains with different fluidity, fusogenicity, and permeability characteristics required for the sperm to navigate to, and to penetrate and fuse with the oocyte.
[0005] Phospholipids are key constituents of the lipid fraction of the sperm cell membranes, with phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin being the major components. The lipid and fatty acid composition of sperm cells differ for different animals and different species as well as for fertile and subfertile population of the same species. Therefore, published data on non-human sperm viability may not be translatable to the performance or viability of human sperm.
[0006] It is known that cryopreservation can affect the sperm membrane of non-human sperm. Further, freezing and thawing results in lipid modifications and domains of the sperm head plasma membrane react differently to cryopreservation.
Furthermore, some studies investigated the ability of sperm cells in boar and bull semen to take up lipid components or fatty acids from the surrounding environment during incubation in vitro.
Furthermore, some studies investigated the ability of sperm cells in boar and bull semen to take up lipid components or fatty acids from the surrounding environment during incubation in vitro.
[0007] (Vasquez and Roldan, 1997) and, furthermore, Buhr et al. (1999) suggested a link between successful cryopreservation of boar semen and a given mixture of lipids and fatty acids in the original diluent. Once again, a specific role for the lipids present in the diluent or exchanges with spermatozoa are indicated.
The present data also indicate that there was not only an uptake of lipid by sperm cells but also that this uptake was related to the quality of fresh semen. Phospholipase activities may mediate this lipid metabolism, totally or in part (for review, see Roldan, 1998).
Buhr et al. (1994) reported an increase in the content of phospholipids, and in particular of phosphatidylcholine, during the cryopreservation of boar spermatozoa in the presence of egg yolk. The exact role of yolk components has not yet been clarified.
Phosphatidylcholine (also called lecithin) has been proposed as the protective component during freezing (Quinn et al., 1980) since it prevented ultrastructural damage and favoured the maintenance of motility and respiration (Simpson et al., 1987). In contrast, studies have shown that phosphatidylcholine had no effect on boar sperm damage (Purse' et at., 1973) and did not prevent motility loss during cold shock and storage at -580 (Watson, 1981). Phosphatidylserine has also been proposed as a protective agent in the boar (Butler and Roberts, 1975; Foulkes, 1977).
Cationic low density lipoprotein (LDL) of egg yolk, characterized by a specific lipid:protein ratio of 2.7, was found to be the most efficient in protecting bull spermatozoa against cold shock. The cationic protein moiety of the LDL complex bound strongly to the sperm plasma membrane, which is negatively charged, and the lipid moiety was responsible for the protective action." (Vishwanath et at., 1992)."Changes In Sperm Quality And Lipid Composition During Cryopreservation Of Boar Semen" S Cerolini, A
Maldjian, F
Pizzi, TM Gliozzi - Reproduction, 2001 - Soc Reprod Fertility.
The present data also indicate that there was not only an uptake of lipid by sperm cells but also that this uptake was related to the quality of fresh semen. Phospholipase activities may mediate this lipid metabolism, totally or in part (for review, see Roldan, 1998).
Buhr et al. (1994) reported an increase in the content of phospholipids, and in particular of phosphatidylcholine, during the cryopreservation of boar spermatozoa in the presence of egg yolk. The exact role of yolk components has not yet been clarified.
Phosphatidylcholine (also called lecithin) has been proposed as the protective component during freezing (Quinn et al., 1980) since it prevented ultrastructural damage and favoured the maintenance of motility and respiration (Simpson et al., 1987). In contrast, studies have shown that phosphatidylcholine had no effect on boar sperm damage (Purse' et at., 1973) and did not prevent motility loss during cold shock and storage at -580 (Watson, 1981). Phosphatidylserine has also been proposed as a protective agent in the boar (Butler and Roberts, 1975; Foulkes, 1977).
Cationic low density lipoprotein (LDL) of egg yolk, characterized by a specific lipid:protein ratio of 2.7, was found to be the most efficient in protecting bull spermatozoa against cold shock. The cationic protein moiety of the LDL complex bound strongly to the sperm plasma membrane, which is negatively charged, and the lipid moiety was responsible for the protective action." (Vishwanath et at., 1992)."Changes In Sperm Quality And Lipid Composition During Cryopreservation Of Boar Semen" S Cerolini, A
Maldjian, F
Pizzi, TM Gliozzi - Reproduction, 2001 - Soc Reprod Fertility.
[0008] The major problem associated with cryopreservation of sperm cells is the loss of viability as a result of the freezing and thawing process. Loss of viability is related to membrane leakiness which is induced by sperm phospholipids peroxidation.
[0009] Infertility issues impact approximately 15% of all couples trying-to-conceive. Male infertility is a contributing factor in about half of these cases and high concentrations of oxidative-stress-causing agents have been identified in 30-80% of infertile men. Studies on the delivery of vitamin supplements and amino acids show an enhancement of specific sperm parameters (count, morphology, motility). Some antioxidants such as these vitamin C, selenium, vitamin E, L carnitine, Vitamin A, zinc and grapeseed extract have been shown to promote healthy sperm count, sperm morphology, and sperm motility, while reducing oxidative damage from agents, free radicals, or biological interactions that causes oxidative stress. (Dawson EB
et al.
Effects of ascorbic acid on male fertility. Ann N V Acad Sci 1987: 498: 312-23).
SUMMARY
et al.
Effects of ascorbic acid on male fertility. Ann N V Acad Sci 1987: 498: 312-23).
SUMMARY
[0010] NT Factor Lipids (NTFL) are compositions containing inulin and purified membrane glycerolphospholipids, as set forth in US Patent 8,877,239 (the 239 patent) and US Patent 9,095,507 (the '507 patent) and US Application Serial Number 14/815,841, all incorporated herein in their entirety by reference, are powerful nutrients for antioxidant therapy and cell membrane repair. The '239 patent describes the formulation and delivery of those phospholipids composition for maintaining or restoring cell and mitochondrial health in the human body, or a specific organ system within the human body, or treating a specific disease or phospholipid deficiency within human body, said composition comprising a mixture of phospholipids or phospholipid precursors including a suitable carrier medium, and particularly in the form of a tablet, capsule or powder. The '507 patent and Serial number 14/815,841 describe and claim delivery of the NTFL compositions in the form of a chewable wafer or tablet.
However, those patents do not show or suggest that the phospholipid compositions, referred to herein as NTFL or NT Factor Lipids, when ingested by a male will enhance the environment within the reproductive organs or semen of the male so as to result in improved vitality and motility of sperm cells produce by that male. Those patents also do not show or suggest that the phospholipid compositions, when ingested by a female will enhance the environment within the female sexual organs or cervical mucus and as a result provide an improved environment to receive the sperm and enhance the sperm motility to increase the likelihood of conception. Nor do those patents show or suggest that the NTFL phospholipids in solution will provide a more suitable fertilization environment and enhanced sperm motility when used in cryopreservation, during in vitro fertilization or prior to or during normal sexual activity intended to result in oocyte fertilization.
However, those patents do not show or suggest that the phospholipid compositions, referred to herein as NTFL or NT Factor Lipids, when ingested by a male will enhance the environment within the reproductive organs or semen of the male so as to result in improved vitality and motility of sperm cells produce by that male. Those patents also do not show or suggest that the phospholipid compositions, when ingested by a female will enhance the environment within the female sexual organs or cervical mucus and as a result provide an improved environment to receive the sperm and enhance the sperm motility to increase the likelihood of conception. Nor do those patents show or suggest that the NTFL phospholipids in solution will provide a more suitable fertilization environment and enhanced sperm motility when used in cryopreservation, during in vitro fertilization or prior to or during normal sexual activity intended to result in oocyte fertilization.
[0011] Set forth herein are the results of incubation of mature spermatozoa from healthy human donors with solutions containing NTFL phospholipids. It has been found by applicants that exposure of spermatozoa to the NTFL phospholipids reduces and/or reverses damage to the exposed spermatozoa and increases sperm motility, particularly in the most mobile sperm, and the resultant increased likelihood of egg fertilization. While data on preservation of animal sperm may not be directly translatable to human, it has been found that human data appears to be relevant to preservation of sperm from livestock used in artificial insemination in animal breeding and similar benefits have been found.
BRIEF DESCRIPTION OF THE DRAWINGS
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 illustrates the elements of sperm motility.
[0013] Figure 2 is a graphical representation of the motility of human sperm.
[0014] Figures 3A and 3B comprise two pie charts comparing the sperm velocity characteristics of a control sperm sample to the same sperm sample after exposure for 3 hourrs to a 1% NTFL concentration.
[0015] Figures 4A and 49 comprise two 3 axis bar charts comparing control sperm samples to 1% NTFL treated sperm.
[0016] Figures 5 is a table comparing the mean amplitude of lateral head displacement and the beat cross frequency of sperm in both the control and following incubation in the 1% NTFL solution.
[0017] Figure 6 is a table comparing the sperm head area (p2) in both the control and following incubation in the 1% NTFL solution.
[0018] Figure 7 is a graph comparing the normal distribution of sperm head size in the Control with the 1% NTFL incubated sample.
[0019] Figure 8 is a semi-log graph illustrating the increase in sperm head area as a function of NTFL for concentrations up to about 2%.
[0020] Figures 9A is a pie cart and Figure 99 is a bar chart illustrating the effect of a 0.1 NTFL solution on a centrifuged sample of sperm.
[0021] Figure 10 is a table illustrating sperm velocity characteristics of centrifuged sperm samples after exposure to the 0.1% NTFL.
[0022] Figures 11A and 11B are graphs showing dose response curves for overall motility and motility of the fastest sperm cells.
[0023] Figures 12A and 12B are pie charts illustrating the effect of low temperature on sperm motility.
[0024] Figures 12C and 12D are 3-dimensional bar charts also illustrating the effect of low temperature on sperm motility.
[0025] Figures 13A and 13B are pie charts illustrating the effect of oxidation on sperm motility.
[0026] Figures 13C and 13D are 3-dimensional bar charts also illustrating the effect of oxidation on sperm motility.
[0027] Figure 14A is a pie chart illustrating that 0.3% NTFL ameliorates the reduction of motility caused by exposure to low temperature.
[0028] Figure 14B is a pie chart illustrating that 0.3% NTFL also ameliorates the reduction of motility caused by exposure to oxidation.
[0029] Figure 14C is a 3-dimensional bar chart also illustrating that exposure to 0.3% NTFL ameliorates the reduction of motility caused by exposure to low temperature.
[0030] Figure 14D is a 3-dimensional bar chart also illustrating that exposure to 0.3% NTFL ameliorates the reduction of motility caused by exposure to H202.
DETAILED DESCRIPTION
DETAILED DESCRIPTION
[0031] NTFL is a phospholipid composition described in US Patent Application No 13/208,255, issued as US Patent No. 8,887,259 incorporated in its entirety herein by reference. Said phospholipid composition comprises inulin and a mixture of phospholipids cornprising phosphatidylglycerol and one or more phospholipids selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylserine (PS), and one or more of linoleic acid (LA) and phosphatidic acid. In a preferred embodiment NTFL phospholipid components comprises19-29% phosphatidylcholine (PC), 15-25% phosphatidylethanolamine (PE), 3.5%- 10% phosphatidic acid (PA), 18% phosphatidylinositol (PI), 2-10% phosphatidylglycerol (PG),10-20%
glycolipids, and 5-11% other phospholipids. This composition along with inulin was used in the studies herein. In another preferred composition mixture of phospholipids having about 25% to about 29% phosphatidylglycerol (PG), about 68% to about 72%
phosphatidylchaline (PC), and up to about 5% phosphatidylethanolarnine (PE), and may optionally include about 1% to about 5% phosphatidylinositol (PI) and phosphatidylserine (PS).
glycolipids, and 5-11% other phospholipids. This composition along with inulin was used in the studies herein. In another preferred composition mixture of phospholipids having about 25% to about 29% phosphatidylglycerol (PG), about 68% to about 72%
phosphatidylchaline (PC), and up to about 5% phosphatidylethanolarnine (PE), and may optionally include about 1% to about 5% phosphatidylinositol (PI) and phosphatidylserine (PS).
[0032] Based on data collected regarding the ability of aqueous solutions of NTFL compositions containing phospholipid to enhance sperm motility in vitro and the ability of ingested NTFL phospholipid compositions to improve mitochondrial heath and function throughout the body, enhanced sperm motility can be provided by delivering the NTFL composition to a male individual to create an enhanced phospholipid environment in said individual's semen or to a female to create an enhanced phospholipid environment in said female individual's vaginal fluids or cervical mucus. The NTFL composition can be delivered in the form of a tablet, capsule or powder as set forth in US Patent 8,877,239. In one embodiment the powdered NTFL may be incorporated in a food product or blended into a suitable liquid and consumed in the form of a beverage, which may be cold or heated. In the alternative, the NTFL powder may be formed into an edible wafer or tablet, for example by compaction in a tablet press such as described in US Patent Applications Ser. No. 14/815,841 and US Patent 9,095.507 referred to above, or divisional or CIP
applications thereof. In a still further embodiment the phospholipid mixture may be included in a vaginal suppository or vaginal lubricant, cream, jelly, foam or gel delivered prior to or directly after sexual intercourse, such as described below. Further, NTH__ compositions containing phospholipids are also beneficial additives in solutions for collecting, storing and preserving (including cryopreservation) live spermatozoa from humans and animals for artificial insemination and in vitro fertilization. Addition of one or more antioxidants such as these vitamin C. selenium, vitamin E, L
carnitine, Vitamin A, zinc and grapeseed extract to the NTFL phospholipid compositions are also beneficial in further enhancing the increase in sperm motility demonstrated by the use of NTFL.
applications thereof. In a still further embodiment the phospholipid mixture may be included in a vaginal suppository or vaginal lubricant, cream, jelly, foam or gel delivered prior to or directly after sexual intercourse, such as described below. Further, NTH__ compositions containing phospholipids are also beneficial additives in solutions for collecting, storing and preserving (including cryopreservation) live spermatozoa from humans and animals for artificial insemination and in vitro fertilization. Addition of one or more antioxidants such as these vitamin C. selenium, vitamin E, L
carnitine, Vitamin A, zinc and grapeseed extract to the NTFL phospholipid compositions are also beneficial in further enhancing the increase in sperm motility demonstrated by the use of NTFL.
[0033] Described below is an evaluation of the beneficial effect of NTFL
phospholipid compositions on the motility of sperm. Increased sperm motility, all other factors remaining constant, will increase the likelihood of an oocyte being penetrated by the sperm, whether in vivo or in vitro, which in turn results in an enhanced likelihood of egg fertilization.
CornparativeTests.
phospholipid compositions on the motility of sperm. Increased sperm motility, all other factors remaining constant, will increase the likelihood of an oocyte being penetrated by the sperm, whether in vivo or in vitro, which in turn results in an enhanced likelihood of egg fertilization.
CornparativeTests.
[0034] Healthy human male participants aged 20 to 51 with no known infertility conditions donated sperm samples (n=12). Using the swim-up method the samples were treated to obtain viable spermatozoa. Multiple comparable portions of the viable spermatazoa were then collected for the comparative evaluations described below.
[0035] Sperm samples were placed in control solutions of HarnF10 (see Table 1) and HamF10 containing NTFL at different concentrations (0.1 to 3% g/m1) and incubated for periods of 1 to 4 hours in an incubator containing a 5% CO2 atmosphere were compared. The NTFL glycerolphospholipids, were found to be incorporated into the spermatozoa membranes in incubations of at least about two hours based on the correlation between sperm head area and NTFL %. After the incubation, the samples were centrifuged at low velocity (approximately 500-1000 RPM in a 10 cm centrifuge, preferably 800 RPM) and later observed in a Leja Chamber for examination with Computer Assisted Sperm Analysis (CASA) (Hirano Y, Shibahara H, Obara H, Suzuki T, Takamizawa S, et al. "Andrology: Relationships Between Sperm Motility Characteristics Assessed By The Computer-Aided Sperm Analysis (CASA) And Fertilization Rates In Vitro". J Assist Reprod Genet (2001);18: 215-220). An average of 10 treatments at 37 C were evaluated (SCA, Microptics). Other samples were treated at lower temperatures (24 C or 30 C), to test the effect of NTFL under stress conditions such as temperature. The same procedure was also performed with samples incubated at 37 C with H202 as a chemical oxidative stress agent.
Ham's F10*
Component ma/It Mol. Wt. Mo1. (m1V1) Amino Acids L-A lanine 89.10000 89.1 1.00 L-Arginine HC1 2107.00000 174.2 12.10 L-Asparagine H20 150.10000 150.1 1.00 L-Aspartic Acid 133.10000 133.1 1.00 L-Cysteine HC1 H20 351.30000 175.6 2.00 L-Glutam ic Acid 147.10000 147.1 1.00 Glycine 75.10000 75.07 1.00 L-Histidine HC1 H20 209.60000 209.6 1.00 L-Isoleucine 26.20000 131.2 0.20 L-Leucine 131.20000 131.2 1.00 L-Lysine HCI 293.00000 182.6 1.60 L-Meth ion ine 44.80000 149.2 0.30 L-Phenylalanine 49.60000 165.2 0.30 L-Prol ine 115.10000 115.1 1.00 L-Serine 105.10000 105.1 1.00 L-Threonine 35.70000 119.1 0.30 L-Tryptophan 6.10000 204.2 0.03 L-Tyrosine 18.10000 181.2 0.10 L-Valine 35.10000 117.1 0.30 Vitamins Biotin 0.24000 244.3 0.0010 Chol ine Chloride 6.98000 139.6 0.05 D-Calcium Pantothenate 7.15000 238.3 0.03 Folic Acid 13.20000 441.4 0.03 myo-lnositol 5.41000 180.2 0.03 N icotinamide 6.11000 122.13 0.05 Pyridoxine HCI 2.06000 205.6 0.01 Riboflavin 3.76000 376.4 0.01 Thiamine HC1 10.12000 337.3 0.03 Vitamin B12 13.60000 1355.4 0.01 Inorganic Salts Calcium Chloride Dihydrate [CaC12 2H20] 441.00000 147.0 3.00 Cupric Sulfate [CuSO4] 0.01600 159.68 0.0001 Ferrous Sulfate Heptahyd rate [FeSO4 7H20] 8.34 278.0 0.03 Magnesium Sulfate [MgSO4] 746.00000 120.4 6.20 Potassium Chloride [Ka] 2850.00000 74.55 38.23 Potassium Phosphate Monobasic [
KH2PO4] 830.00000 136.09 6.10 Sodium Chloride [NaCI] 74000.00000 58.44 1266.26 Sodium Phosphate Dibasic [Na2HPO4] 1562.00000 141.96 11.00 Zinc Sulfate Heptahydrate [ZnSO4 7H20] 0.28800 287.5 0.0010 Other Dextrose 11000.00000 180.2 61.04 Hypoxanthine 40.80000 136.1 0.30 Lipoic Acid 2.06000 206.3 0.01 Phenol Red Sodium Salt 12.40000 376.4 0.03 Sodium Pyruvate 1100.00000 110.0 10.00 Thymidine 7.27000 242.2 *Ham, R.G., Exptl. Cell Res., v. 39, 515 (1963).
Ham's F10*
Component ma/It Mol. Wt. Mo1. (m1V1) Amino Acids L-A lanine 89.10000 89.1 1.00 L-Arginine HC1 2107.00000 174.2 12.10 L-Asparagine H20 150.10000 150.1 1.00 L-Aspartic Acid 133.10000 133.1 1.00 L-Cysteine HC1 H20 351.30000 175.6 2.00 L-Glutam ic Acid 147.10000 147.1 1.00 Glycine 75.10000 75.07 1.00 L-Histidine HC1 H20 209.60000 209.6 1.00 L-Isoleucine 26.20000 131.2 0.20 L-Leucine 131.20000 131.2 1.00 L-Lysine HCI 293.00000 182.6 1.60 L-Meth ion ine 44.80000 149.2 0.30 L-Phenylalanine 49.60000 165.2 0.30 L-Prol ine 115.10000 115.1 1.00 L-Serine 105.10000 105.1 1.00 L-Threonine 35.70000 119.1 0.30 L-Tryptophan 6.10000 204.2 0.03 L-Tyrosine 18.10000 181.2 0.10 L-Valine 35.10000 117.1 0.30 Vitamins Biotin 0.24000 244.3 0.0010 Chol ine Chloride 6.98000 139.6 0.05 D-Calcium Pantothenate 7.15000 238.3 0.03 Folic Acid 13.20000 441.4 0.03 myo-lnositol 5.41000 180.2 0.03 N icotinamide 6.11000 122.13 0.05 Pyridoxine HCI 2.06000 205.6 0.01 Riboflavin 3.76000 376.4 0.01 Thiamine HC1 10.12000 337.3 0.03 Vitamin B12 13.60000 1355.4 0.01 Inorganic Salts Calcium Chloride Dihydrate [CaC12 2H20] 441.00000 147.0 3.00 Cupric Sulfate [CuSO4] 0.01600 159.68 0.0001 Ferrous Sulfate Heptahyd rate [FeSO4 7H20] 8.34 278.0 0.03 Magnesium Sulfate [MgSO4] 746.00000 120.4 6.20 Potassium Chloride [Ka] 2850.00000 74.55 38.23 Potassium Phosphate Monobasic [
KH2PO4] 830.00000 136.09 6.10 Sodium Chloride [NaCI] 74000.00000 58.44 1266.26 Sodium Phosphate Dibasic [Na2HPO4] 1562.00000 141.96 11.00 Zinc Sulfate Heptahydrate [ZnSO4 7H20] 0.28800 287.5 0.0010 Other Dextrose 11000.00000 180.2 61.04 Hypoxanthine 40.80000 136.1 0.30 Lipoic Acid 2.06000 206.3 0.01 Phenol Red Sodium Salt 12.40000 376.4 0.03 Sodium Pyruvate 1100.00000 110.0 10.00 Thymidine 7.27000 242.2 *Ham, R.G., Exptl. Cell Res., v. 39, 515 (1963).
[0036] Figure 1 illustrates the elements of sperm motility where:
= VCL Curvilinear velocity ¨ Velocity of sperm in a trajectory for progression = VSL ¨ Progressive velocity ¨ Velocity of sperm in an axis straight line for progression = VAP ¨ Average velocity Velocity measured on a mean sperm trajectory for progression. All velocities are measured in pM/s) = L1N ¨ Linearity ¨ Ratio of axis straight line and curved trajectory velocities (VSL/VCL) = STR ¨ Straightness Ratio of straight line and mean trajectory velocities (VSLA/AP) = WOB ¨ Oscillation index ¨ Oscillation of trajectory about an spatial average path. These indexes are expressed as ./0 = ALH ¨ Amplitude of the lateral displacement of the head from mean axis straight line (pM) = BCF ¨ Beat Cross Frequency ¨ Number of times per second that sperm crosses the Mean axis straight line (Hz) Figure 1 shows the characteristics of motility and velocity of human sperm (usually measured in micrometer/sec). The solid line curve (VCL) represents the actual curvilinear velocity or track of a single motile sperm cell, whereas the dashed line curve represents the average velocity (VAP) of many sperm cells. The movement consists of the amplitude of lateral movement or displacement (ALH) of the sperm head from a straight line and progressive (forward or straight-line) movement (VSL).
The straightness velocity of movement (STR) can be defined as VSLA/APX100. The figure illustrates all the motility parameters shown in the WHO manual on sperm studies to be relevant to fertility.
= VCL Curvilinear velocity ¨ Velocity of sperm in a trajectory for progression = VSL ¨ Progressive velocity ¨ Velocity of sperm in an axis straight line for progression = VAP ¨ Average velocity Velocity measured on a mean sperm trajectory for progression. All velocities are measured in pM/s) = L1N ¨ Linearity ¨ Ratio of axis straight line and curved trajectory velocities (VSL/VCL) = STR ¨ Straightness Ratio of straight line and mean trajectory velocities (VSLA/AP) = WOB ¨ Oscillation index ¨ Oscillation of trajectory about an spatial average path. These indexes are expressed as ./0 = ALH ¨ Amplitude of the lateral displacement of the head from mean axis straight line (pM) = BCF ¨ Beat Cross Frequency ¨ Number of times per second that sperm crosses the Mean axis straight line (Hz) Figure 1 shows the characteristics of motility and velocity of human sperm (usually measured in micrometer/sec). The solid line curve (VCL) represents the actual curvilinear velocity or track of a single motile sperm cell, whereas the dashed line curve represents the average velocity (VAP) of many sperm cells. The movement consists of the amplitude of lateral movement or displacement (ALH) of the sperm head from a straight line and progressive (forward or straight-line) movement (VSL).
The straightness velocity of movement (STR) can be defined as VSLA/APX100. The figure illustrates all the motility parameters shown in the WHO manual on sperm studies to be relevant to fertility.
[0037] Figure 2 is a graphical representation showing the distribution of sperm motility in a typical collected sample (identified as mobile) with the sample broken down into three classifications, namely, slow, medium and rapid and, within each classification the curvilinear and average velocity.
[0038]The differences between those motilities, are explained in the WHO
Laboratory Manual For Examination And Processing Of Human Semen (5th Edition), World Health Organization, (2010). According to the Manual, when discussing sperm motility, it is important to specify total motility (PR + NP) or progressive motility (PR). A simple system for grading motility is recommended that distinguishes spermatozoa with progressive or non-progressive motility from those that are immotile. The motility of each spermatozoon is graded as follows:
a. Progressive motility (PR): spermatozoa moving actively, either linearly or in a large circle, regardless of speed;
b. Non-progressive motility (NP): all other patterns of motility with an absence of progression, e.g. swimming in small circles, the flagellar force hardly displacing the head, or when only a flagellar beat can be observed; and c. lmmotility (IM): no movement_ The previous edition of this manual recommended that progressively motile spermatozoa should be categorized as rapid or slow, with a speed of >25 _m/sec at 37 "C defining "grade a" spermatozoa. However, it is difficult for technicians to define the forward progression so accurately without bias (Cooper &Yeung, 2006).
Laboratory Manual For Examination And Processing Of Human Semen (5th Edition), World Health Organization, (2010). According to the Manual, when discussing sperm motility, it is important to specify total motility (PR + NP) or progressive motility (PR). A simple system for grading motility is recommended that distinguishes spermatozoa with progressive or non-progressive motility from those that are immotile. The motility of each spermatozoon is graded as follows:
a. Progressive motility (PR): spermatozoa moving actively, either linearly or in a large circle, regardless of speed;
b. Non-progressive motility (NP): all other patterns of motility with an absence of progression, e.g. swimming in small circles, the flagellar force hardly displacing the head, or when only a flagellar beat can be observed; and c. lmmotility (IM): no movement_ The previous edition of this manual recommended that progressively motile spermatozoa should be categorized as rapid or slow, with a speed of >25 _m/sec at 37 "C defining "grade a" spermatozoa. However, it is difficult for technicians to define the forward progression so accurately without bias (Cooper &Yeung, 2006).
[0039]Fig. 2 shows a typical experiment and the data that results from analysis of the various parameters of sperm motility showing an average motility (all motile or mobile sperm) and the sperm motility separated into several velocity categories specifically slow, medium and rapidly moving motile sperm.
[0040] The pie charts in Fig 3 show progressive motility as fast, medium and slow and non-progressive motility, immotile spermatozoa percentage (static).
Slow progressive motility is represented by slow or medium mobile sperm. Figures 3A
and 3B show the distribution of sperm activity for a control sperm sample (Fig.
3A) compared to the same sperm sample after exposure for 3 hrs to a 1% NTH_ concentration (Fig. 3B). The data shows significant improvements in sperm motility but this can only be seen at lower NTFL concentrations where the NTFL micelles don't interfere with sperm motility as a result of impact of NTFL micelles with sperm. For example, in concentrations between 0.01 and 0.3%, particularly from 0.1-0.3%, sonicated, micro-emulsified NTFL samples sperm motility was increased. This was also found in sperm samples at the higher NTFL concentrations (1%) where the sperm were separated from the NTFL micelles by brief centrifugation. In other words, sperm motility was actually significantly increased in the sample with 1% NTFL, but the increase could not be properly measured due to the sperm collision with NTFL
micelles.
Slow progressive motility is represented by slow or medium mobile sperm. Figures 3A
and 3B show the distribution of sperm activity for a control sperm sample (Fig.
3A) compared to the same sperm sample after exposure for 3 hrs to a 1% NTH_ concentration (Fig. 3B). The data shows significant improvements in sperm motility but this can only be seen at lower NTFL concentrations where the NTFL micelles don't interfere with sperm motility as a result of impact of NTFL micelles with sperm. For example, in concentrations between 0.01 and 0.3%, particularly from 0.1-0.3%, sonicated, micro-emulsified NTFL samples sperm motility was increased. This was also found in sperm samples at the higher NTFL concentrations (1%) where the sperm were separated from the NTFL micelles by brief centrifugation. In other words, sperm motility was actually significantly increased in the sample with 1% NTFL, but the increase could not be properly measured due to the sperm collision with NTFL
micelles.
[0041] Figures 4A and 4B are 3 axis bar charts comparing the same control sperm samples to 1% NTFL treated sperm as in Figs 3A and 3B. At NTFL
concentrations near 1% the overall velocities of sperm in the sample were reduced due to micelle collisions and motility interference. The bars in the right row of the chart illustrate mobile, rapidly moving sperm involved in collisions with relatively large lipid micelles. Motile sperm, however, had an average increase in velocities (VCL, VSL, VAP, LIN, STR, WOB) of 18 4% (p<0.05 independent t-test).
concentrations near 1% the overall velocities of sperm in the sample were reduced due to micelle collisions and motility interference. The bars in the right row of the chart illustrate mobile, rapidly moving sperm involved in collisions with relatively large lipid micelles. Motile sperm, however, had an average increase in velocities (VCL, VSL, VAP, LIN, STR, WOB) of 18 4% (p<0.05 independent t-test).
[0042] Figures 5 is a table comparing the mean amplitude of lateral head displacement (ALH) and the beat cross frequency (BCF) of sperm in both the control and following incubation in the 1% NTFL solution. The presence of NTFL
phospholipids increases ALH and BCF which are critical for fertility prediction in a sperm sample. These parameters related to flagella activity, especially BCF, which are indicative of the strength of penetration during fertility, were also increased by approximately the same amount and at the same significance level.
phospholipids increases ALH and BCF which are critical for fertility prediction in a sperm sample. These parameters related to flagella activity, especially BCF, which are indicative of the strength of penetration during fertility, were also increased by approximately the same amount and at the same significance level.
[0043] To test if the NTFL composition becomes incorporated into the sperm membrane, changes in the sperm head area were determined. Figure 6 is a table comparing the sperm head area (p2) in both the control and following incubation in the 1% NTFL phospholipid solution. A statistically significant increase in sperm head velocity was found to occur in all NTFL incubated sperm cells in the sample, indicating a significant incorporation of the NTFL into each sperm cell. Alternatively, it was found that a comparison of a 123 Rhodamine stained control sperm sample with a stained sperm sample in a NTFL 0.02% solution, even when exposed to 300 uM of H202, showed a significant increase in cytoplasmic droplets in spermatozoa in a confocal field of sperm seeded at the same concentration (an increase from 12 % to 72%, p<0.05). 123 Rhodamine stains mostly mitochondrial membranes and plasma membrane regions in the midpiece, neck and subequatorial head of the sperm cell. Xu, Yuan et al. (2013) has pointed that the presence of cytoplasmic droplets is indicative of healthy and motile sperm (Hui Xu, Shui-Qiao Yuan, Zhi-Hong Zheng, and Wei Yan, "The Cytoplasmic Droplet May Be Indicative Of Sperm Motility And Normal Spermiogenesis", Asian J Andral. (2013 Nov); 15(6): 799-805).
[0044] Figure 7 is a graph comparing the normal distribution of sperm head size in control solutions with equivalent sperm samples incubated in a 1% NTFL
solutions.
The significant increase in sperm head area from an average of 16 pm in the Control to 19 pm in the NTFL solution (p<0.05, independent t-test) and a greater distribution thereof shows that NTFL incorporates into the sperm head..
[8045] Figure 8 is a graph (semi-log) illustrating the increase in sperm head area as a function of NTFL solution concentrations for concentrations up to about 2%
in the solution showing that sperm head area increases as the concentration increases.
[0046] Figure 9A is a pie chart and Figure 9B is a 3 dimensional bar chart illustrating the effect of a 0.1 NTFL solution on a centrifuged sample of sperm.
Recognizing that NTFL incorporates into the sperm head, the interference resulting from the presence of micelles was reduced by preparing centrifuged sperm samples to separate the sperm from the lipid micelles. At lower NTFL concentrations the velocities of all sperm were found to be increased. Separation of the sperm cells from the lipid micelles by low speed centrifugation made the enhanced motility of sperm cells by the presence of even a small amount of NTFL more obvious. In addition, sonication and micro-emulsification of NTFL, showed significantly improvement at NTFL
concentrations between 0.01 to 0.3 %.
[0047] Figure 10 is a Table illustrating the sperm velocity characteristics of the centrifuged sperm samples after exposure to the 0.1% NTFL. While centrifuging enhanced the characteristics of the Control sample, ALH and BCF are still increased by exposure to 0.1%NTFL centrifuged sperm samples, showing its usefulness at these concentrations to promote hyperactivated states (increase of BCE), which is associated with better fertility and healthier sperm. This effect is even more pronounced in the fastest spermatozoa, meaning that the presence of NTFL
improves all sperm but is even more effective on the fastest spermatozoa which are the best sperm for causing egg fertilization.
[0048] Figures 11A and 11B show dose response curves for overall motility and motility of the fastest sperm cells. Both velocities are increased upon centrifugation.
However, at concentrations approaching 1% there is a tendency for a reduction in motility because of micelle interference and the head is probably too heavy for the flagella to properly function. The effect is more pronounced and has an 1050 of approximately 0.5% for the fastest sperm compared with overall motile sperm.
When cells were separated from the lipid micelles by low speed centrifugation, the enhanced motility of sperm cells was more obvious for overall and fastest motility, with increasing NTFL concentration.
[0049] Figures 12A, 12B, 120, 12D, 13A, 13B, 13C and 13D illustrate the effect of low temperature or oxidation respectively on sperm motility. Increasing oxidative stress with hydrogen peroxide or stress by physical means, such as lowering temperatures, decreases sperm motility, and thus all sperm velocities were reduced (Figs. 13a and 13B). Also, the fraction of static or non-mobile spermatozoa was increased.
[0050] Figures 14A, 14B, 140 and 140 show that exposure to 0.3% NTFL
ameliorates the reduction of motility caused by exposure to lower temperatures or exposure to H202, illustrating that NTFL is also an effective agent to protect spermatozoa against oxidative damage, which is one of the primary causes of male infertility.
[0051] Based on the data set forth in the Figures and discussed above it is concluded that the motility and capacity of active sperm in the semen obtained from healthy donors is improved by exposure to NTFL. Although the benefits of using concentrations of NTFL near 1% are not readily seen without centrifugation to remove large NTFL micelles that result in collisions with sperm, exposure of sperm to NTFL
concentrations below 1% were shown to be real and reproducible. Motile sperm exposed to NTFL had an average increase in sperm velocity parameters (VOL, VSL, VAP, LIN, STR, WOB) of 18.4%. Sperm motility parameters related to flagella activity, which is an indication of the ability to penetrate ovum during fertilization, were also increased by approximately the same degree (ALH and BCF) [0052] Confirming that the NTFL was incorporated into sperm membranes was shown by the increase in sperm head size (increase in sperm head membrane area) during incubation with NTFL. The average size of the sperm heads increased with NTFL concentrations, from an average of 16 urn to 19 urn. When sperm cells were separated from the lipid micelles by low speed (about 500-1000 RPM) centrifugation, the enhanced motility of the sperm cells was more obvious in the overall sperm population.
[0053] Dose-response curves for overall motility effects showed an IC50 of approx. 0,5 %, with motility increments with exposure to 0.1%-0.3%NTFL. Even under stress produced by low temperature or oxidation (hydrogen peroxide) exposures, swim-up results obtained for sperm exposed to a 0.1% NTFL solution maintained overall motility and the velocities and flagella assessment showed increases of about 20% for the highly motile sperm which comprises the sperm population primarily responsible for fertilization.
[0054] Human sperm exposed to, or stored in a solution containing an NTFL
composition is effective in protecting sperm functionality against damage by physical or oxidative stress. The NTFL composition is a specific combination of inulin with membrane glycerolphospholipids selected to maintain or enhance the normal sperm cell membrane phospholipid composition. A preferred NTFL composition comprises inulin and a mixture of phospholipids comprising phosphatidylglycerol and one or more phospholipids selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylserine (PS), and one or more of linoleic acid (LA) and phosphatidic acid. In a more preferred embodiment NTFL phospholipid components comprises 19-29% phosphatidylcholine (PC), 15-25% phosphatidylethanolamine (PE), 3.5%- 10% phosphatidic acid (PA), 18% phosphatidylinositol (PI), 2-10% phosphatidylglycerol (PG) 10-20%
glycolipids, and 5-11% other phospholipids. Alternatively, a preferred composition mixture of phospholipids has about 25% to about 29% phosphatidylglycerol (PG), about 68%
to about 72% phosphatidylcholine (PC), and up to about 5%
phosphatidylethanolamine (PE), and may alternatively include optionally further comprising about 1% to about 5%
phosphatidylinositol (P1) and phosphatidylserine (PS).
[0055] Accordingly, since it has been shown that ingestion of NTFL
compositions including glycerolphospholipids results in the dissemination and incorporation of the glycerolphospholipids into cellular membranes throughout the body, ingestion of NTFL compositions including phospholipids by a male are expected to result in the incorporation of NTFL phospholipids into sperm cells and the environment where sperm are produced and stored in the body resulting in greater sperm motility in semen.
[0056] Further, based thereon it is concluded that exposure of sperm to NTFL
compositions including the phospholipids during sperm development and production (spermatogenesis), storage or maturation in males will increase the quality and motility of sperm, and in particular, the quality and motility of the most active and motile fraction of sperm that are most likely to be involved in fertilization. Thus even when the male is considered to be infertile due to lowered sperm motility, or has impaired sperm motility as a result of aging, oxidative stress, variations in ambient temperature or adverse physical conditions, such as elevated inflammation or other conditions, NTFL compositions including pholipids are expected to increase the quality and enhance the motility of ejaculated sperm.
[0057] Administering NTFL compositions including phospholipids to a male over a period of time is expected to result in an improvement in the quality of sperm produced by that individual. Administering NTFL compositions including phospholipids to a female over a period of time will likewise enhance the environment in which the sperm is placed and also increase fecundity of the female, thus increasing the likelihood of conception. Thus, the use of NTFL compositions by both males and females further enhance fertility and the likelihood of successful fertilization. It appears that these results can also be applied to livestock reproduction particularly in bovines by artificial means.
[0058] It is further concluded that ingestion, or other forms of delivery of the NTFL composition to a female, for example, using an NTFL containing suppository, by placement of a solution of NTFL within the vagina prior to intercourse or artificial insemination will create an environment for enhanced motility of the sperm subsequently introduced into the vagina.
[0059] For example, a fertility enhancing vaginally deliverable NTFL
composition can be formed by replacing the nonoxyno1-9, or other spermicidal additives with NTFL in vaginal spermicidal creams, jellies, foams, gels, and suppositories or adding NTFL to vaginal lubricants.
[0060] Administering NTFL to a male over a period of time will result in an improvement in the quality of sperm produced by that individual, administering NTFL
to a female over a period of time will likewise enhance the environment in which the sperm is placed and may also increase fecundity of the female, thus increasing the likelihood of conception, and the use of NTFL compositions by both the male and female will further enhance the likelihood of the sperm fertilizing and oocyte.
solutions.
The significant increase in sperm head area from an average of 16 pm in the Control to 19 pm in the NTFL solution (p<0.05, independent t-test) and a greater distribution thereof shows that NTFL incorporates into the sperm head..
[8045] Figure 8 is a graph (semi-log) illustrating the increase in sperm head area as a function of NTFL solution concentrations for concentrations up to about 2%
in the solution showing that sperm head area increases as the concentration increases.
[0046] Figure 9A is a pie chart and Figure 9B is a 3 dimensional bar chart illustrating the effect of a 0.1 NTFL solution on a centrifuged sample of sperm.
Recognizing that NTFL incorporates into the sperm head, the interference resulting from the presence of micelles was reduced by preparing centrifuged sperm samples to separate the sperm from the lipid micelles. At lower NTFL concentrations the velocities of all sperm were found to be increased. Separation of the sperm cells from the lipid micelles by low speed centrifugation made the enhanced motility of sperm cells by the presence of even a small amount of NTFL more obvious. In addition, sonication and micro-emulsification of NTFL, showed significantly improvement at NTFL
concentrations between 0.01 to 0.3 %.
[0047] Figure 10 is a Table illustrating the sperm velocity characteristics of the centrifuged sperm samples after exposure to the 0.1% NTFL. While centrifuging enhanced the characteristics of the Control sample, ALH and BCF are still increased by exposure to 0.1%NTFL centrifuged sperm samples, showing its usefulness at these concentrations to promote hyperactivated states (increase of BCE), which is associated with better fertility and healthier sperm. This effect is even more pronounced in the fastest spermatozoa, meaning that the presence of NTFL
improves all sperm but is even more effective on the fastest spermatozoa which are the best sperm for causing egg fertilization.
[0048] Figures 11A and 11B show dose response curves for overall motility and motility of the fastest sperm cells. Both velocities are increased upon centrifugation.
However, at concentrations approaching 1% there is a tendency for a reduction in motility because of micelle interference and the head is probably too heavy for the flagella to properly function. The effect is more pronounced and has an 1050 of approximately 0.5% for the fastest sperm compared with overall motile sperm.
When cells were separated from the lipid micelles by low speed centrifugation, the enhanced motility of sperm cells was more obvious for overall and fastest motility, with increasing NTFL concentration.
[0049] Figures 12A, 12B, 120, 12D, 13A, 13B, 13C and 13D illustrate the effect of low temperature or oxidation respectively on sperm motility. Increasing oxidative stress with hydrogen peroxide or stress by physical means, such as lowering temperatures, decreases sperm motility, and thus all sperm velocities were reduced (Figs. 13a and 13B). Also, the fraction of static or non-mobile spermatozoa was increased.
[0050] Figures 14A, 14B, 140 and 140 show that exposure to 0.3% NTFL
ameliorates the reduction of motility caused by exposure to lower temperatures or exposure to H202, illustrating that NTFL is also an effective agent to protect spermatozoa against oxidative damage, which is one of the primary causes of male infertility.
[0051] Based on the data set forth in the Figures and discussed above it is concluded that the motility and capacity of active sperm in the semen obtained from healthy donors is improved by exposure to NTFL. Although the benefits of using concentrations of NTFL near 1% are not readily seen without centrifugation to remove large NTFL micelles that result in collisions with sperm, exposure of sperm to NTFL
concentrations below 1% were shown to be real and reproducible. Motile sperm exposed to NTFL had an average increase in sperm velocity parameters (VOL, VSL, VAP, LIN, STR, WOB) of 18.4%. Sperm motility parameters related to flagella activity, which is an indication of the ability to penetrate ovum during fertilization, were also increased by approximately the same degree (ALH and BCF) [0052] Confirming that the NTFL was incorporated into sperm membranes was shown by the increase in sperm head size (increase in sperm head membrane area) during incubation with NTFL. The average size of the sperm heads increased with NTFL concentrations, from an average of 16 urn to 19 urn. When sperm cells were separated from the lipid micelles by low speed (about 500-1000 RPM) centrifugation, the enhanced motility of the sperm cells was more obvious in the overall sperm population.
[0053] Dose-response curves for overall motility effects showed an IC50 of approx. 0,5 %, with motility increments with exposure to 0.1%-0.3%NTFL. Even under stress produced by low temperature or oxidation (hydrogen peroxide) exposures, swim-up results obtained for sperm exposed to a 0.1% NTFL solution maintained overall motility and the velocities and flagella assessment showed increases of about 20% for the highly motile sperm which comprises the sperm population primarily responsible for fertilization.
[0054] Human sperm exposed to, or stored in a solution containing an NTFL
composition is effective in protecting sperm functionality against damage by physical or oxidative stress. The NTFL composition is a specific combination of inulin with membrane glycerolphospholipids selected to maintain or enhance the normal sperm cell membrane phospholipid composition. A preferred NTFL composition comprises inulin and a mixture of phospholipids comprising phosphatidylglycerol and one or more phospholipids selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylserine (PS), and one or more of linoleic acid (LA) and phosphatidic acid. In a more preferred embodiment NTFL phospholipid components comprises 19-29% phosphatidylcholine (PC), 15-25% phosphatidylethanolamine (PE), 3.5%- 10% phosphatidic acid (PA), 18% phosphatidylinositol (PI), 2-10% phosphatidylglycerol (PG) 10-20%
glycolipids, and 5-11% other phospholipids. Alternatively, a preferred composition mixture of phospholipids has about 25% to about 29% phosphatidylglycerol (PG), about 68%
to about 72% phosphatidylcholine (PC), and up to about 5%
phosphatidylethanolamine (PE), and may alternatively include optionally further comprising about 1% to about 5%
phosphatidylinositol (P1) and phosphatidylserine (PS).
[0055] Accordingly, since it has been shown that ingestion of NTFL
compositions including glycerolphospholipids results in the dissemination and incorporation of the glycerolphospholipids into cellular membranes throughout the body, ingestion of NTFL compositions including phospholipids by a male are expected to result in the incorporation of NTFL phospholipids into sperm cells and the environment where sperm are produced and stored in the body resulting in greater sperm motility in semen.
[0056] Further, based thereon it is concluded that exposure of sperm to NTFL
compositions including the phospholipids during sperm development and production (spermatogenesis), storage or maturation in males will increase the quality and motility of sperm, and in particular, the quality and motility of the most active and motile fraction of sperm that are most likely to be involved in fertilization. Thus even when the male is considered to be infertile due to lowered sperm motility, or has impaired sperm motility as a result of aging, oxidative stress, variations in ambient temperature or adverse physical conditions, such as elevated inflammation or other conditions, NTFL compositions including pholipids are expected to increase the quality and enhance the motility of ejaculated sperm.
[0057] Administering NTFL compositions including phospholipids to a male over a period of time is expected to result in an improvement in the quality of sperm produced by that individual. Administering NTFL compositions including phospholipids to a female over a period of time will likewise enhance the environment in which the sperm is placed and also increase fecundity of the female, thus increasing the likelihood of conception. Thus, the use of NTFL compositions by both males and females further enhance fertility and the likelihood of successful fertilization. It appears that these results can also be applied to livestock reproduction particularly in bovines by artificial means.
[0058] It is further concluded that ingestion, or other forms of delivery of the NTFL composition to a female, for example, using an NTFL containing suppository, by placement of a solution of NTFL within the vagina prior to intercourse or artificial insemination will create an environment for enhanced motility of the sperm subsequently introduced into the vagina.
[0059] For example, a fertility enhancing vaginally deliverable NTFL
composition can be formed by replacing the nonoxyno1-9, or other spermicidal additives with NTFL in vaginal spermicidal creams, jellies, foams, gels, and suppositories or adding NTFL to vaginal lubricants.
[0060] Administering NTFL to a male over a period of time will result in an improvement in the quality of sperm produced by that individual, administering NTFL
to a female over a period of time will likewise enhance the environment in which the sperm is placed and may also increase fecundity of the female, thus increasing the likelihood of conception, and the use of NTFL compositions by both the male and female will further enhance the likelihood of the sperm fertilizing and oocyte.
Claims (23)
1. A method of increasing sperm motility comprising delivering to a male mammal, a female mammal or both the male and female mammal a composition comprising inulin and a mixture of phospholipids.
2. The method of claim 1 wherein the mixture of phospholipids comprises phosphatidylglycerol and one or more phospholipids selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylserine (PS), and one or more of linoleic acid (LA) and phosphatidic acid.
3. The method of claim 1 wherein the composition is delivered in the form of a. a tablet, capsule or powder, said powder added to a food product, blended into a beverage or compressed into a chewable tablet or b. provided as 0.1 to 4% of a vaginal cream, jelly, foam, gel, or lubricants or a suppository.
4. The method of claim 1 wherein the phospholipid mixture comprises:
19-29% phosphatidylcholine (PC), 15-25% phosphatidylethanolamine (PE), 3.5%- 10% phosphatidic acid (PA), 10-18% phosphatidylinositol (PI), 2-10% phosphatidylglycerol (PG), 10-20% glycolipides and 5-11% other phospholipids.
19-29% phosphatidylcholine (PC), 15-25% phosphatidylethanolamine (PE), 3.5%- 10% phosphatidic acid (PA), 10-18% phosphatidylinositol (PI), 2-10% phosphatidylglycerol (PG), 10-20% glycolipides and 5-11% other phospholipids.
5. A method of increasing the likelihood of fertilization of a female oocyte by a sperm cell comprising delivering to a mammalian male, female or both the male and female a composition comprising inulin and a mixture of phospholipids.
S. The method of claim 5 wherein the mixture of phospholipids comprises phosphatidylglycerol and one or more phospholipids selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylserine (PS), and one or more of linoleic acid (LA) and phosphatidic acid.
7. The method of claim 5 wherein the composition is delivered in the form of a. a tablet, capsule or powder, said powder added to a food product, blended into a beverage or compressed into a chewable tablet, or b. provided as 0.1 to 4% of a vaginal cream, jelly, foam, gel, or lubricants or a suppository.
8. The method of claim 5 wherein the phospholipid mixture comprises:
19-29% phosphatidylcholine (PC), 15-25% phosphatidylethanolamine (PE), 3.5%- 10% phosphatidic acid (PA), 10-18% phosphatidylinositol (PI), 2-10% phosphatidylglycerol (PG), 10-20% glycolipides and 5-11% other phospholipids.
19-29% phosphatidylcholine (PC), 15-25% phosphatidylethanolamine (PE), 3.5%- 10% phosphatidic acid (PA), 10-18% phosphatidylinositol (PI), 2-10% phosphatidylglycerol (PG), 10-20% glycolipides and 5-11% other phospholipids.
9. A method of increasing the motility of sperm comprising depositing the sperm in an aqueous solution comprising inulin and a mixture of phospholipids.
10. The method of claim 9 wherein the mixture of phospholipids comprises phosphatidylglycerol and one or more phospholipids selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylserine (PS), and one or more of linoleic acid (LA) and phosphatidic acid.
11.The method of claim 9 wherein the inulin and the mixture of phospholipids comprises 0.1 to 4% of the aqueous solution.
12. The method of claim 9 wherein the phospholipid mixture comprises:
19-29% phosphatidylcholine (PC), 15-25% phosphatidylethanolamine (PE), 3.5%- 10% phosphatidic acid (PA), 10-18% phosphatidylinositol (PI), 2-10% phosphatidylglycerol (PG), 10-20% glycolipides and 5-11% other phospholipids.
19-29% phosphatidylcholine (PC), 15-25% phosphatidylethanolamine (PE), 3.5%- 10% phosphatidic acid (PA), 10-18% phosphatidylinositol (PI), 2-10% phosphatidylglycerol (PG), 10-20% glycolipides and 5-11% other phospholipids.
13. A sperm motility enhancing composition comprising an aqueous solution of inulin and a mixture of phospholipids.
14. The sperm motility enhancing composition of claim 13 further comprising amino acids, vitamins and inorganic salts.
15. The sperm motility enhancing composition of claim 13 wherein the phospholipid mixture comprising phosphatidylglycerol and one or more phospholipids selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylserine (PS), and one or more of linoleic acid (LA) and phosphatidic acid.
16.The sperm motility enhancing composition of claim 13 further including an antioxidant.
17.The sperm motility enhancing composition of claim 16 wherein the antioxidant comprises one or more of vitamin C, selenium, vitamin E, L carnitine, Vitamin A, zinc and grapeseed extract.
18.The sperm motility enhancing composition of claim 13 wherein the inulin and the mixture of phospholipids comprises 0.1 to 4% of the aqueous solution.
19.The sperm motility enhancing composition of claim 13 wherein the phospholipid mixture comprises:
19.The sperm motility enhancing composition of claim 13 wherein the phospholipid mixture comprises:
19-29% phosphatidylcholine (PC), 15-25% phosphatidylethanolamine (PE), 3.5%- 10% phosphatidic acid (PA), 10-18% phosphatidylinositol (PI), 2-10% phosphatidylglycerol (PG), 10-20% glycolipides and 5-11% other phospholipids.
20.A method of increasing the likelihood of fertilization of a female ovum in vitro by a sperm cell comprising placing the sperm cells in an aqueous composition comprising inulin and a mixture of phospholipids.
21.The method of claim 20 where in the mixture of phospholipids comprises phosphatidylglycerol and one or more phospholipids selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylserine (PS), and one or more of linoleic acid (LA) and phosphatidic acid.
22. The method of claim 20 wherein said inulin and phospholipids comprise 0.1 to 4% of the aqueous solution.
23.The method of claim 20 wherein the phospholipid mixture comprises:
19-29% phosphatidylcholine (PC), 15-25% phosphatidylethanolamine (PE), 3.5%- 10% phosphatidic acid (PA), 10-18% phosphatidylinositol (PI), 2-10% phosphatidylglycerol (PG), 10-20% glycolipides and 5-11% other phospholipids.
19-29% phosphatidylcholine (PC), 15-25% phosphatidylethanolamine (PE), 3.5%- 10% phosphatidic acid (PA), 10-18% phosphatidylinositol (PI), 2-10% phosphatidylglycerol (PG), 10-20% glycolipides and 5-11% other phospholipids.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562216269P | 2015-09-09 | 2015-09-09 | |
US62/216,269 | 2015-09-09 | ||
US201562245868P | 2015-10-23 | 2015-10-23 | |
US62/245,868 | 2015-10-23 | ||
US15/256,245 | 2016-09-02 | ||
PCT/US2016/050282 WO2017044393A1 (en) | 2015-09-09 | 2016-09-02 | Phospholipid compositions and use thereof to enhance spermatozoa motility and viability |
US15/256,245 US9861656B2 (en) | 2007-08-08 | 2016-09-02 | Phospholipid compositions and use thereof to enhance spermatozoa motility and viability |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2998325A1 true CA2998325A1 (en) | 2017-03-16 |
Family
ID=58239858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2998325A Abandoned CA2998325A1 (en) | 2015-09-09 | 2016-09-02 | Phospholipid compositions and use thereof to enhance spermatozoa motility and viability |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2018531917A (en) |
CA (1) | CA2998325A1 (en) |
WO (1) | WO2017044393A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200205399A1 (en) * | 2017-07-31 | 2020-07-02 | Two Cells Co., Ltd. | Composition for cryopreservation, method for producing cryopreserved material, cell preparation, method for producing cell preparation, and kit for cryopreservation |
WO2020068023A1 (en) * | 2018-09-27 | 2020-04-02 | Yildiz Tekni̇k Üni̇versi̇tesi̇ | Composition intended for increasing the velocity of sperms comprising serotonin as active compound |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000002087A (en) * | 1998-06-17 | 2000-01-15 | 김형민 | New use of inulin as anti-cancer medicine and pharmaceutic composition containing inulin |
GB9906009D0 (en) * | 1999-03-16 | 1999-05-12 | Nycomed Pharma As | Product |
JP2008259506A (en) * | 2007-03-20 | 2008-10-30 | Tokyo Univ Of Agriculture | Bovine frozen semen for artificial insemination |
US8877239B2 (en) * | 2010-08-12 | 2014-11-04 | Nutritional Therapeutics, Inc. | Lipid supplements for maintaining health and treatment of acute and chronic disorders |
US9095507B2 (en) * | 2011-08-11 | 2015-08-04 | Allergy Research Group, Llc | Chewable wafers containing lipid supplements for maintaining health and the treatment of acute and chronic disorders |
JP2013519372A (en) * | 2010-02-12 | 2013-05-30 | アンドロゲニックス・リミテッド | How to improve sperm functionality |
WO2012103685A1 (en) * | 2011-02-01 | 2012-08-09 | Nippon Suisan Kaisha, Ltd. | Sexual function improving agent |
EP2780032B1 (en) * | 2013-01-10 | 2018-03-28 | Allergy Research Group, LLC | Chewable wafers containing lipid supplements for maintaining health and the treatment of acute and chronic disorders |
-
2016
- 2016-09-02 WO PCT/US2016/050282 patent/WO2017044393A1/en active Application Filing
- 2016-09-02 JP JP2018513556A patent/JP2018531917A/en active Pending
- 2016-09-02 CA CA2998325A patent/CA2998325A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2017044393A1 (en) | 2017-03-16 |
JP2018531917A (en) | 2018-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9861656B2 (en) | Phospholipid compositions and use thereof to enhance spermatozoa motility and viability | |
Bustani et al. | Semen extenders: An evaluative overview of preservative mechanisms of semen and semen extenders | |
Câmara et al. | Effects of reduced glutathione and catalase on the kinematics and membrane functionality of sperm during liquid storage of ram semen | |
Tuncer et al. | The effect of cysteine and glutathione on sperm and oxidative stress parameters of post-thawed bull semen | |
Crespilho et al. | Comparison of in vitro and in vivo fertilizing potential of bovine semen frozen in egg yolk or new lecithin based extenders | |
Shahverdi et al. | Fertility and flow cytometric evaluations of frozen-thawed rooster semen in cryopreservation medium containing low-density lipoprotein | |
Muiño et al. | Effects of cryopreservation on the motile sperm subpopulations in semen from Asturiana de los Valles bulls | |
Masoudi et al. | Effect of dietary fish oil supplementation on ram semen freeze ability and fertility using soybean lecithin–and egg yolk–based extenders | |
Garde et al. | The application of reproductive technologies to natural populations of red deer | |
Askarianzadeh et al. | Sperm quality characteristics and fertilization capacity after cryopreservation of rooster semen in extender exposed to a magnetic field | |
Del Valle et al. | Function of ram spermatozoa frozen in diluents supplemented with casein and vegetable oils | |
Abdi-Benemar et al. | Effects of DHA supplementation of the extender containing egg yolk and α-tocopherol on the freezability and post-thawing fertility of ram semen | |
Falchi et al. | Cerium dioxide nanoparticles did not alter the functional and morphologic characteristics of ram sperm during short-term exposure | |
DE60006675T2 (en) | METHOD FOR IMPROVING THE FERTILIZING ACTIVITY OF SPERMATOZOA | |
Yamaguchi et al. | Effect of the addition of beta-mercaptoethanol to a thawing solution supplemented with caffeine on the function of frozen-thawed boar sperm and on the fertility of sows after artificial insemination | |
Motta et al. | Effects of melatonin supplementation on the quality of cryopreserved sperm in the neotropical fish Prochilodus lineatus | |
CA2998325A1 (en) | Phospholipid compositions and use thereof to enhance spermatozoa motility and viability | |
Kledmanee et al. | Effect of L-cysteine on chilled carp (Cyprinus carpio) semen qualities | |
Heidari et al. | L-carnitine improves quality parameters and epigenetic patterns of buck’s frozen-thawed semen | |
Khalique et al. | Antioxidant effects of zinc-oxide nanoparticles on post-thaw quality and in vivo fertility of Beetal buck spermatozoa | |
Abe et al. | Artificial insemination with canine spermatozoa frozen in a skim milk/glucose-based extender | |
Nurcholis et al. | Supplementation of pandanus conoideus oil in cryopreservation diluents for maintaining the semen quality of ongole grade bull | |
Kaeoket et al. | The effect of using long term and short term extenders during cooling process on the quality of frozen boar semen | |
Lee et al. | Effect of alpha-linolenic acid with bovine serum albumin or methyl-beta-cyclodextrin on membrane integrity and oxidative stress of frozen-thawed boar sperm | |
Tar et al. | Effects of different ultrastructures of lecithin on cryosurvival of goat spermatozoa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20200911 |
|
FZDE | Discontinued |
Effective date: 20230302 |
|
FZDE | Discontinued |
Effective date: 20230302 |